Khanzode 2003.

Methods	Twelve‐week, prospective, open‐label, randomised study
Participants	Patients with major depression according to the DSM‐IV criteria. Exclusion criteria: patients having a score less than 14 were excluded from the study, patients with other axis I and axis II diagnoses besides major depression. Medical illnesses including endocrine, metabolic or autoimmune disorders known to affect free radical status
Interventions	Citalopram: 33 participants. Fluoxetine: 34 participants. Citalopram dose: 20 mg/day. Fluoxetine dose: 20 mg/die.
Outcomes	Primary outcome: MDA and SOD concentration levels. Secondary outcomes: change in Hamilton Depression Rating Scale (HDRS) score from baseline to week 12.
Notes	Indian study.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "patients who were suitable for drug treatment were allocated randomly".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding (performance bias and detection bias) All outcomes	High risk	Open label study.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided.
Selective reporting (reporting bias)	Unclear risk	No information provided.
Other bias	Unclear risk	Sponsorship bias cannot be ruled out.